Karuna Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Karuna Therapeutics generated cash of -$385,819,000, which is less than the previous year. Cash used in financing activities reached the amount of $483,373,000 last year. Net change in cash is therefore -$62,767,000.
Cash Flow
| 2017 | -4.02M | -13K | 4.25M |
|---|---|---|---|
| 2018 | -15.37M | -5.11M | 27.57M |
| 2019 | -30.92M | -174.33M | 405.28M |
| 2020 | -69.85M | -89.65M | 3.65M |
| 2021 | -100.87M | -22.68M | 277.57M |
| 2022 | -228.00M | -586.39M | 855.77M |
| 2023 | -385.81M | -160.32M | 483.37M |
KRTX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 248.59M | 207.21M | 53.20M | 209.05M | 9.02M | 1.94M | 1.73M |
Operating activities | |||||||
Net income | -433.68M | -276.33M | -143.80M | -68.55M | -43.95M | -17.51M | -6.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.70M | 1.11M | 506K | 145K | 58K | 6K | 1K |
Stock-based compensation expense | 74.59M | 47.45M | 29.81M | 13.47M | 12.56M | 958K | 215K |
| Deferred income tax benefit | 74.59M | 47.45M | 29.81M | 13.47M | 12.56M | 958K | 215K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 57K | 1.69M | -1.75M | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 4.34M | 243K | 1.07M | 318K | 278K | -529K | 537K |
Cash generated by operating activities | -385.81M | -228.00M | -100.87M | -69.85M | -30.92M | -15.37M | -4.02M |
Investing activities | |||||||
Purchases Of Investments | -1.52B | -930.28M | -400.82M | -344.21M | -231.71M | -4.98M | 0 |
Investments In Property Plant And Equipment | -2.91M | -915K | -3.07M | -419K | -115K | -132K | -13K |
Acquisitions Net | 3.92M | 1.22M | 3.14M | 419K | 115K | 0 | 0 |
Cash generated by investing activities | -160.32M | -586.39M | -22.68M | -89.65M | -174.33M | -5.11M | -13K |
Financing activities | |||||||
Common Stock Issued | 487.89M | 0 | 0 | 3.65M | 330.07M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 483.37M | 855.77M | 277.57M | 3.65M | 405.28M | 27.57M | 4.25M |
Net Change In Cash | -62.76M | 41.37M | 154.00M | -155.84M | 200.02M | 7.08M | 210K |
Cash at end of period | 185.82M | 248.59M | 207.21M | 53.20M | 209.05M | 9.02M | 1.94M |
| Data source | Data source | Data source | Data source | Data source |